A critical functional advantage of the scFv over the native T-cell receptor (TCR) is its ability to bind antigen independently of major histocompatibility complex (MHC) molecules, enabling recognition of a broader range of tumor targets [2,17]. This evidence concerns the gene HLA-C and neoplasm.